Royalty Pharma has acquired a royalty interest from Neurimmune in AstraZeneca’s cliramitug, a Phase 3 drug targeting ATTR-CM, for up to $425 million including $125 million upfront. Cliramitug is designed to remove amyloid deposits in the heart, potentially transforming treatment for this fatal disease. The drug is in late-stage trials with results expected in 2028, and AstraZeneca projects peak sales of $3-5 billion. This deal strengthens Royalty Pharma’s portfolio in a growing market with significant unmet medical needs.
AstraZeneca reported second-quarter earnings that surpassed analyst expectations, with core earnings per share rising 21% to $2.63, though revenue slightly missed forecasts at $15.4 billion. Growth in oncology and rare diseases offset weaker sales fr...
Jefferies maintains a buy rating on AstraZeneca, highlighting that detailed data on its lung drug tozorakimab, due on 8 September, could offset the impact of a failed heart trial. The lung drug targets IL-33, potentially benefiting a broader COPD pat...
Jefferies maintains a buy rating on AstraZeneca, expecting detailed data on its lung drug tozorakimab in September to compensate for a recent heart trial failure. The failed CARDIO-TTRansform study cut $4 billion from forecasts, but Jefferies believe...
